Diagnostic Significance and Clinical Implications of Increased Liver Echogenicity

Definition and Causes

Increased liver echogenicity is defined as higher echogenicity of liver parenchyma compared to the renal cortex on ultrasound examination, primarily indicating fatty infiltration (steatosis), which can be an early sign of non-alcoholic fatty liver disease (NAFLD) 1, 2
The primary cause is hepatic steatosis (fatty liver), where lipid droplets within hepatocytes disturb sound wave propagation, causing scatter and attenuation 3
This scatter results in more echoes returning to the ultrasound transducer, making the liver appear brighter than normal tissue 3

Grading criteria for steatosis based on echogenicity include mild, moderate, and severe increases in liver echogenicity, with moderate being increased echogenicity with slightly impaired visualization of intrahepatic vessels and diaphragm, and severe being marked increase in echogenicity with poor or non-visualization of intrahepatic vessels, posterior portion of the liver, and diaphragm 2
Additional sonographic features of fatty liver include attenuation of ultrasound waves causing depth-dependent loss of signal, and obscuration of vessels, bile ducts, and blurring of the diaphragm 3

Ultrasound has high sensitivity (84.8%) and specificity (93.6%) for moderate to severe hepatic fat deposition 2
Technical factors such as gain settings can artificially alter the apparent echogenicity, potentially leading to misdiagnosis 2

Increased echogenicity should prompt evaluation for NAFLD, especially in patients with risk factors such as obesity, type 2 diabetes, or metabolic syndrome, according to the American Gastroenterological Association 1
Initial evaluation should include liver biochemistries (ALT, AST), exclusion of other liver diseases through serological testing (HBV, HCV, autoantibodies), and assessment of alcohol intake (should be <14 drinks/week for women, <21 drinks/week for men to diagnose NAFLD) 1
Risk stratification for advanced fibrosis is recommended using non-invasive fibrosis scores (NAFLD fibrosis score, Fibrosis-4 Index), and elastography-based tests for patients at intermediate or high risk 1
Liver biopsy remains the gold standard for definitive diagnosis and staging of liver disease when clinical uncertainty exists, as recommended by the American Gastroenterological Association 1

Fatty liver can mask underlying focal lesions due to increased background echogenicity 2
Ultrasound assessment should be standardized by comparing liver echogenicity to kidney (hepatorenal index) for more objective evaluation 2

The American College of Radiology recommends considering other conditions that can produce an echogenic liver, such as cirrhosis, which cannot be reliably differentiated from fatty liver based on echogenicity alone, with a sensitivity of 84.8% and specificity of 93.6% for detecting moderate to severe hepatic fat deposition in patients with increased liver echogenicity 4, 5
The sonographic appearance of hepatic steatosis and cirrhosis often overlap, with a "fatty-fibrotic" pattern, and increased echogenicity cannot reliably diagnose or exclude fibrosis or cirrhosis in patients with liver disease 4, 5, 6
Ultrasound has limited sensitivity (53-65%) for detecting mild hepatic steatosis, and gain settings can artificially alter apparent echogenicity, potentially causing misdiagnosis in patients with fatty liver disease 4, 5

For intermediate or high-risk patients, the American College of Radiology recommends performing elastography-based assessment (transient elastography or ARFI) to evaluate liver fibrosis, with liver biopsy remaining the gold standard when clinical uncertainty exists 4, 5
Patients with echogenic liver and metabolic risk factors, such as obesity, type 2 diabetes, hypertension, and dyslipidemia, require optimization of diabetes, hypertension, and dyslipidemia control, and have a significantly higher risk of progression to cirrhosis or hepatocellular carcinoma 4, 5, 6